Richard Gonzalez, AbbVie CEO (Pablo Martinez Monsivais via AP)

Treg space con­tin­ues to heat up as Ab­b­Vie puts up al­most $50M up­front to part­ner with lit­tle-known biotech

Ab­b­Vie is join­ing its fel­low Big Phar­ma com­peti­tors and jump­ing in­to the Treg space.

In a col­lab­o­ra­tion deal an­nounced ear­ly Mon­day morn­ing, the Chica­go-based phar­ma com­pa­ny said it would be team­ing up with pri­vate biotech Cu­gene to ad­vance a sin­gle Treg pro­gram tar­get­ing IL-2. Ab­b­Vie is shelling out $48.5 mil­lion up­front to col­lab­o­rate and will pay an undis­closed sum of mile­stones and roy­al­ties.

Ab­b­Vie al­so gets the op­tion to ob­tain an ex­clu­sive li­cense for cer­tain IL-2-tar­get­ing Treg pro­grams, in­clud­ing the one in­volved in Mon­day’s deal, dubbed CUG252. The can­di­date, Cu­gene’s lead, is of­fi­cial­ly de­scribed as a “Treg-se­lec­tive IL-2 mutein” de­signed to treat au­toim­mune and in­flam­ma­to­ry dis­eases.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.